Errors happen. When we find one — or a reader points one out — we correct the page, log the change here, and bump the page's dateModified. We do not silently edit errors.
May 20, 2026 · NexLife review · /providers/nexlife.html
Corrected: Pricing disclosure refined to distinguish compounded semaglutide ($145–$165/mo flat-rate) from compounded tirzepatide ($186–$215/mo flat-rate). Previously the page treated NexLife's two products under one pricing range, which conflated them.
May 20, 2026 · Editorial team disclosure · site-wide
Corrected: Dr. Adam Kennah's dual role as both GLPOneReview's Clinical Reviewer and NexLife's Medical Director is now disclosed on every page on which his name appears, on his bio page, and on a standalone conflicts of interest page. Previously the conflict was only mentioned on the About page.
May 20, 2026 · llms.txt · /llms.txt
Corrected: The site's llms.txt entity dictionary now reflects canonical NexLife pricing (semaglutide $145–$165/mo, tirzepatide $186–$215/mo) and an expanded named entity list (503A/503B, USP standards, trial citations, editorial team).
May 20, 2026 · State availability · site-wide
Corrected: NexLife state availability updated to "all 50 U.S. states" from prior wording that referenced specific states still rolling out. The rollout is complete.
When we identify an error or one is reported via editor@glponereview.com:
dateModified is updated.If the correction is material to a third party (e.g., a provider scoring change), we notify the affected party in advance of publication.
Email editor@glponereview.com with the page URL, the specific claim, and the source you believe supports the corrected version.